The agency narrowed who can get the shot and added new study requirements that could cost the company tens of millions.

Novavax originally showed its vaccine was safe and effective in a 30,000-person clinical trial. The FDA had been on track to grant Novavax full approval – without restrictions -- by its April 1 target ...